Dr. Austin Kim, MD

Dr. Kim practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Kim's NPI, 1366753618, was assigned on July 1, 2010. Dr. Kim graduated from Geisel School Of Medicine At Dartmouth in 2010. Dr. Kim's Massachusetts license number on file is 254376.

Dr. Kim's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Kim's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Kim is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Kim to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kim practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kim's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kim is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kim's licenses on file in 3 states: Massachusetts, Rhode Island and Vermont.

Dmand AI lists chronic anemia, chronic leukemia, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Kim treats.

CMS data shows 597 Medicare services from Dr. Kim across 7 procedure codes in 2024, for 270 Medicare patients. Medicare paid $51,753 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 270 Medicare patients who saw Dr. Kim in 2024. The largest group is 65 to 74, with 126 patients. 69% of them have high cholesterol, and 68% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kim's median patient age at 70, with 45% women.

In 2024, Dr. Kim wrote 401 Medicare Part D claims for 88 patients. 64% of them were for generic drugs. CMS names the drug for 268 of them, across 10 drugs with 11 or more claims each, at $1,598,563 in total drug cost. In 2023, CMS named 316 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Kim for performance year 2024, reported as part of a group. Dr. Kim accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kim as offering telehealth.

Dmand AI links 34 papers to Dr. Kim, published from 2014 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Autologous and Antineoplastic Combined Chemotherapy Protocols. Dr. Kim has published most often in Blood Adv. Dr. Kim's most frequent co-authors are Caron Alyce Jacobson, MD, Ann S. Lacasce, MD and Philippe Armand, MD, PhD.

Dmand AI links Dr. Kim to 2 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell and Lymphoma, B-Cell.

CMS Open Payments shows 3 general payments to Dr. Kim from 2 drug and device companies from 2017 to 2019. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $135. It also lists 2 research payments totaling $3,281 from 2024 to 2025.

Dr. Kim graduated from Geisel School Of Medicine At Dartmouth in 2010.

Dr. Kim is in network with 14 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.